Cell receptor genetically engineered T cell therapy is to improve specific tumor recognition by transducing chimeric antigen receptor (fusion antigen binding domain and cell signaling domain) or TCRα/β heterodimer into ordinary T cells.
The affinity of TCR of related antigens (Tumor Associated Antigen, TAA) and the fighting power of immune cells enable T lymphocytes to efficiently recognize target cells and exert strong anti-tumor immune effects in vivo
.
T-cell-based immunotherapy, including CAR-T therapy, TCR-T therapy and TILs therapy, has come out
.
Drug research and development (Photo source: Pharmaceutical Network)
At present, TCR-T therapy mainly targets the solid tumor market and has become a research hotspot internationally, but the global TCR-T therapy industry is still in the experimental research stage
.
It is reported that at present, local companies are also accelerating the deployment of the TCR-T field, thereby promoting the development of the TCR-T therapy industry
.
Among them, Xiangxue Pharma started to carry out tumor drug development and TCR-T therapy research using TCR in 2012, and built a high-affinity immunotherapy drug development, clinical treatment technology development and transformation platform with TCR-T technology as the core
.
In September 2020, Xiangxue Precision's TCRT-ESO-A2 new drug clinical trial application, a subsidiary of Xiangxue Pharmaceutical Holdings, was approved by the US FDA, becoming the first TCR-T project in China to receive FDA clinical trial approval
.
The data shows that the clinical trial project is a TCR-T project for the treatment of solid tumors, which is used to treat solid tumors whose tissue genotype is HLA-A*02:01 and the tumor antigen NY-ESO-1 expression is positive
.
In addition, there are many domestic pharmaceutical companies such as Tiankeya, Kerui Bio, Fosun Kite, WuXi Junuo, Shenzhen Inno Immunity, Guangzhou Laien Biopharmaceuticals, Shenzhen Binder Biopharmaceuticals, etc.
, which have already deployed in the TCR-T field.
.
Such as Tiankeya has developed 3 different types of TCR-T products
.
For example, the first type of product is mainly traditional TCR-T, that is, only loaded with TCR.
At present, investigator-initiated clinical trials (IIT) have been carried out, and dozens of patients have been included
.
Relying on the CHECK-T technology platform, the second type of products is loaded with the more mature PD-1/L1 in the selection of targets for releasing immunosuppression.
There are already 5 types of the second type of products, targeting cervical cancer and non-small cell lung cancer respectively.
, melanoma, sarcoma, nasopharyngeal carcinoma, NK/T cell lymphoma, ovarian cancer and endometrioma
.
There are two types of products loaded with tumor microenvironment repair factors in the third category, targeting nasopharyngeal cancer, ovarian cancer and endometrioma respectively
.
With the mission of "innovating biotechnology, lighting up hope for life", Kerui Bio is currently developing a number of first-in-class TCR-T cell immunotherapy drugs and TCR-based T cell bridging bispecific antibody protein drugs.
Contains cell therapy products targeting KRAS G12 mutation and TCR protein drugs for the treatment of HPV infectious diseases
.
According to relevant persons, facing the high technical barriers of TCR-T, Kerui Bio has completed the establishment of the TCR epitope identification platform, the single-cell and library-based TCR cloning platform, and the SMART-TCR affinity optimization platform.
The efficiency of TCR screening and the success rate of affinity optimization have broken through the development bottleneck of TCR-T cell drugs, and have the ability to develop soluble TCR protein drugs
.
According to the industry, TCR-T is one of the directions that has attracted much attention in recent years, and will bring new breakthroughs to conquering solid tumors
.
Another person also said that TCR-T therapy currently shows great potential in preclinical and clinical research.
Although there are still many challenges, with the innovation and accumulation of technology, it is believed that TCR-T will show a unique future in the future.
It is attractive and brings hope to cancer patients to relieve their pain
.
It is understood that with the continuous increase of new tumor patients, the demand for TCR-T therapy will also grow rapidly, and the market for TCR-T therapy is expected to accelerate in the next five years
.
According to the forecast of potential demand for TCR-T therapy in China, the market size of China's TCR-T therapy industry may increase from 38.
70 billion yuan in 2021 to 104.
14 billion yuan in 2025, with a compound annual growth rate of 28.
1%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
